SCHEMBL23363642

SCHEMBL23363642

CC(=O)Oc1cccc(OCc2ccc(C(=O)O)cc2)c1C=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 9/20 0.56
RXRB P28702 8/20 0.56
RXRG P48443 6/20 0.56
HPGD P15428 2/20 0.52
FOLH1 Q04609 1/20 0.51
ATM Q13315 1/20 0.48
PTGER1 P34995 1/20 0.47
PTGER4 P35408 1/20 0.47
PTGER3 P43115 1/20 0.47
PTGER2 P43116 1/20 0.47
KDM4E B2RXH2 2/20 0.46
MAPT P10636 2/20 0.46
KMT2A Q03164 2/20 0.46
PSMD14 O00487 1/20 0.46
ALDH1A1 P00352 1/20 0.46
CRHBP P24387 1/20 0.46
PPARG P37231 1/20 0.46
CRHR2 Q13324 1/20 0.46
CTDSP1 Q9GZU7 1/20 0.46
SRD5A2 P31213 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30495975 1.00 RXRA (0.56) RXRARXRBRXRGHPGDFOLH1
SCHEMBL23383976 0.87 RXRA (0.70) RXRARXRBRXRGHPGDFOLH1
SCHEMBL21798467 0.84 RXRA (0.70) RXRARXRBRXRGHPGDFOLH1
Tucaresol SCHEMBL29400654 0.83 RXRA (0.56) RXRARXRBRXRGHPGDFOLH1
Tucaresol SCHEMBL600942 0.83 RXRA (0.56) RXRARXRBRXRGHPGDFOLH1
SCHEMBL6026702 0.81 BRD4 (0.59) RXRARXRBRXRGHPGDFOLH1
SCHEMBL17826400 0.80 FOLH1 (0.54) RXRARXRBRXRGHPGDFOLH1
SCHEMBL23384170 0.79 RXRA (0.51) RXRARXRBRXRGHPGDFOLH1
SCHEMBL10923656 0.79 TP53 (0.54) HPGDFOLH1PTGER1KDM4EKMT2A
SCHEMBL6341223 0.78 KMT2A (0.66) RXRARXRBRXRGHPGDPTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112778155-B Tucarbaryl derivatives and uses thereof 大连万春布林医药有限公司 2023-08-11 CN disclosed
US-20220387365-A1 TUCARESOL DERIVATIVES AND USES THEREOF BEYONDSPRING PHARMACEUTICALS, INC. 2022-12-08 US disclosed
US-20220387365-A1 TUCARESOL DERIVATIVES AND USES THEREOF BEYONDSPRING PHARMACEUTICALS, INC. 2022-12-08 US disclosed
EP-4058427-A1 TUCARESOL DERIVATIVES AND USES THEREOF Beyondspring Pharmaceuticals Inc. (US) 2022-09-21 EP disclosed
WO-2021096811-A1 TUCARESOL DERIVATIVES AND USES THEREOF BEYONDSPRING PHARMACEUTICALS, INC. (US) 2021-05-20 WO disclosed
WO-2021096811-A1 TUCARESOL DERIVATIVES AND USES THEREOF BEYONDSPRING PHARMACEUTICALS, INC. (US) 2021-05-20 WO disclosed
CN-112778155-A Turcatecol derivatives and uses thereof 万春药业公司 2021-05-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220387365-A1 TUCARESOL DERIVATIVES AND USES THEREOF ICOS, TEX264, PBK RXRA 1594/4885RXRB 1704/4885RXRG 1707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.